Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2024 | 3155 | 0.510 |
Why?
|
| Receptor, ErbB-2 | 5 | 2024 | 280 | 0.380 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 512 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 2543 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 1447 | 0.240 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 157 | 0.240 |
Why?
|
| Kupffer Cells | 1 | 2024 | 13 | 0.220 |
Why?
|
| Fluorouracil | 2 | 2024 | 524 | 0.220 |
Why?
|
| Everolimus | 1 | 2024 | 34 | 0.210 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 47 | 0.200 |
Why?
|
| Leucovorin | 1 | 2024 | 200 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2017 | 576 | 0.180 |
Why?
|
| Machine Learning | 1 | 2024 | 346 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2024 | 151 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2024 | 578 | 0.150 |
Why?
|
| Biomarkers, Tumor | 4 | 2017 | 1660 | 0.140 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 29 | 0.140 |
Why?
|
| Asthma | 2 | 2017 | 1039 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 773 | 0.140 |
Why?
|
| Bevacizumab | 2 | 2016 | 254 | 0.130 |
Why?
|
| Urogenital Neoplasms | 1 | 2017 | 24 | 0.130 |
Why?
|
| Pathology | 1 | 2017 | 36 | 0.130 |
Why?
|
| Mastectomy | 2 | 2016 | 262 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 110 | 0.120 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 121 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 1054 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2016 | 107 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 244 | 0.110 |
Why?
|
| Receptors, Progesterone | 3 | 2024 | 195 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 226 | 0.110 |
Why?
|
| Mesothelioma | 1 | 2017 | 331 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 236 | 0.100 |
Why?
|
| Receptors, Estrogen | 3 | 2024 | 412 | 0.100 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 26 | 0.100 |
Why?
|
| Melanoma | 1 | 2017 | 494 | 0.100 |
Why?
|
| Taxoids | 3 | 2020 | 126 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 621 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2024 | 2009 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 810 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 1171 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 795 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1073 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 1071 | 0.080 |
Why?
|
| Female | 12 | 2024 | 48542 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 537 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2013 | 403 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2301 | 0.070 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 278 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 1786 | 0.070 |
Why?
|
| Humans | 15 | 2024 | 93132 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1130 | 0.070 |
Why?
|
| Middle Aged | 7 | 2024 | 27535 | 0.070 |
Why?
|
| Anthracyclines | 2 | 2020 | 31 | 0.070 |
Why?
|
| Aged | 6 | 2024 | 20395 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 360 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 570 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2363 | 0.060 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2024 | 8 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 984 | 0.050 |
Why?
|
| Adult | 5 | 2024 | 27849 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2024 | 91 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2024 | 165 | 0.050 |
Why?
|
| DNA Damage | 1 | 2024 | 389 | 0.050 |
Why?
|
| United States | 4 | 2016 | 7581 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1703 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 1060 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 1529 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 16 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 86 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 226 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 1260 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 80 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 283 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 2757 | 0.040 |
Why?
|
| Postmenopause | 1 | 2018 | 106 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2018 | 170 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 4546 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 223 | 0.030 |
Why?
|
| Pathologists | 1 | 2017 | 40 | 0.030 |
Why?
|
| Self-Management | 1 | 2017 | 44 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 51 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 85 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2017 | 93 | 0.030 |
Why?
|
| Child | 2 | 2017 | 7273 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 167 | 0.030 |
Why?
|
| Male | 3 | 2024 | 44355 | 0.030 |
Why?
|
| Capecitabine | 1 | 2015 | 97 | 0.030 |
Why?
|
| Mammaplasty | 1 | 2016 | 122 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1727 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2015 | 207 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 401 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1172 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 885 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 381 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 874 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2016 | 369 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1719 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 482 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 1945 | 0.020 |
Why?
|
| Chicago | 1 | 2017 | 1452 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1518 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 27973 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 446 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1304 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 2545 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1898 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 12230 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3781 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2013 | 618 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1517 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3814 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5900 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 6922 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 9070 | 0.020 |
Why?
|